Group 1: Company Overview and Activities - Guizhou Langma Information Technology Co., Ltd. participated in the 2025 Guizhou Listed Companies Investor Reception Day and 2024 Annual Performance Briefing on May 12, 2025 [2] - The event was held online via the "Panorama Roadshow" platform, with key personnel including Chairman and General Manager Mr. Wang Wei and other executives present [2] Group 2: Product Development and Revenue - The "39AI Doctor Brain" is continuously being updated and optimized, with a focus on meeting user needs and commercializing with B-end clients such as hospitals and pharmaceutical companies [2] - The "39AI Doctor" product has been launched with features like disease diagnosis and case analysis, generating revenue in some medical institutions and pharmaceutical companies, but not significantly impacting overall company performance yet [2][3] Group 3: Financial Performance and International Revenue - The company's foreign revenue for 2024 was reported at 894,500 yuan, which constitutes a small percentage of total revenue, indicating minimal impact from current tariff policies [3] - Other income in the 2024 annual report includes software sales, rental income, and property management services [3] Group 4: Share Repurchase Plans - The company currently has no plans for share repurchase; any significant matters regarding share repurchase will be announced in accordance with regulations [3]